2m 2m 2m 2m 2m 2m 2m
Neurocrine Biosc (NBIX)
NASDAQ
$164.78+$3.16 (+1.95%)
Price as of Jun 23, 2026 5:12 PM EDT- $16.3BMarket Cap
- 28.47%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Neurocrine Biosc (NBIX)
$164.78+$3.16 (+1.95%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.8B +20.32% | 2.4B +24.81% | 1.9B +26.76% | 1.5B +31.34% | |
Cost of Revenue | 52.1M +53.24% | 34.0M -14.36% | 39.7M +71.12% | 23.2M +62.24% | |
Gross Profit | 2.8B +19.84% | 2.3B +25.65% | 1.8B +26.06% | 1.5B +30.94% | |
Sales and Marketing Expense | 1.2B +14.79% | 1.0B +13.47% | 887.6M +17.92% | 752.7M +29.04% | |
Research and Development Expense | -1.0B +38.93% | -731.1M +29.40% | -565.0M -221.82% | 463.8M N/A | |
Depreciation and Amortization Expense | 4.1M +13.89% | 3.6M +2.86% | 3.5M +600.00% | 500,000 -95.41% | |
Total Operating Expenses | 2.2B +25.58% | 1.8B +9.08% | 1.6B +31.98% | 1.2B +20.24% | |
Operating Profit | 619.1M +8.52% | 570.5M +127.38% | 250.9M +0.76% | 249.0M +142.93% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -4.6M -35.21% | -7.1M -72.48% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -4.6M -164.79% | 7.1M -72.48% | |
Total Nonoperating Income and Expense | 86.3M +202.13% | -84.5M -204.06% | 81.2M +331.34% | -35.1M +3,090.91% | |
Income before Taxes | 705.4M +45.14% | 486.0M +46.34% | 332.1M +55.26% | 213.9M +110.95% | |
Income Taxes | 226.8M +56.74% | 144.7M +75.61% | 82.4M +38.72% | 59.4M +403.39% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 478.6M +40.23% | 341.3M +36.68% | 249.7M +61.62% | 154.5M +72.43% | |
Net Income from Continuing Operations Applicable to Common | 705.4M +45.14% | 486.0M +46.34% | 332.1M +55.26% | 213.9M +110.95% | |
Basic EPS and Net Income | 4.81 +41.47% | 3.40 +32.81% | 2.56 +59.01% | 1.61 +69.47% | |
Diluted EPS and Net Income | 4.67 +41.95% | 3.29 +33.20% | 2.47 +58.33% | 1.56 +69.57% | |
Basic Weighted Average Shares | 99.5M -0.90% | 100.4M +2.76% | 97.7M +1.98% | 95.8M +1.27% | |
Diluted Weighted Average Shares | 102.5M -1.16% | 103.7M +2.67% | 101.0M +2.12% | 98.9M +1.02% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 713.0M +206.01% | 233.0M -7.21% | 251.1M -4.49% | 262.9M -22.86% | |
Short-Term Investments | 767.4M -8.98% | 843.1M +8.02% | 780.5M +7.45% | 726.4M +96.06% | |
Cash and Cash Equivalents and Short-Term Investments | 1.5B +37.57% | 1.1B +4.31% | 1.0B +4.28% | 989.3M +39.08% | |
Total Current Assets | 2.5B +46.27% | 1.7B +7.32% | 1.6B +10.56% | 1.5B +49.41% | |
Accumulated Depreciation | 118.3M +11.08% | 106.5M +28.31% | 83.0M +25.19% | 66.3M +27.75% | |
Property and Plant and Equipment and Net | 89.8M +8.72% | 82.6M +16.67% | 70.8M +20.82% | 58.6M 0.00% | |
Total Long-Term Assets | 59.5M +283.87% | 15.5M -68.75% | 49.6M +98.40% | 25.0M +468.18% | |
Total Assets | 4.6B +24.55% | 3.7B +14.37% | 3.3B +37.27% | 2.4B +14.29% | |
Income Taxes Payable | 282.5M +75.79% | 160.7M +33.47% | 120.4M +1,316.16% | -9.9M -1.00% | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 170.1M +0.41% | 169.4M N/A | |
Total Current Liabilities | 743.4M +46.43% | 507.7M -22.46% | 654.8M +21.78% | 537.7M +118.76% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Total Long-Term Liabilities | 219.7M +32.19% | 166.2M +56.35% | 106.3M +257.91% | 29.7M +141.46% | |
Total Liabilities | 1.4B +22.09% | 1.1B +10.75% | 1.0B +54.24% | 660.9M -5.38% | |
Retained Earnings | 447.7M +1,433.22% | 29.2M +118.59% | -157.1M -61.38% | -406.8M -36.02% | |
Total Stockholders Equity | 3.3B +25.62% | 2.6B +16.03% | 2.2B +30.69% | 1.7B +24.29% | |
Total Shares Outstanding | 100.1M +0.70% | 99.4M +0.71% | 98.7M +2.28% | 96.5M +1.69% | |
Cash Flow | |||||
Cash from Operating Activities | 782.7M +31.46% | 595.4M +52.71% | 389.9M +14.88% | 339.4M +32.32% | |
Capital Expenditures | 34.0M -10.99% | 38.2M +34.98% | 28.3M +71.52% | 16.5M -29.49% | |
Cash from Investing Activities | -264.4M +108.52% | -126.8M -72.85% | -467.1M +163.75% | -177.1M +36.02% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -38.3M -92.13% | -486.7M -845.33% | 65.3M +127.87% | -234.3M -955.11% | |
Financials Ratio | |||||
Gross Margin | 98.16% -0.40% | 98.56% +0.67% | 97.90% -0.55% | 98.44% -0.30% | |
Operating Margin | 21.85% -9.81% | 24.22% +82.18% | 13.30% -20.51% | 16.73% +84.96% | |
Return on Assets | 11.46% +17.05% | 9.79% +10.21% | 8.89% +27.72% | 6.96% +47.82% | |
Return on Equity | 16.38% +15.72% | 14.16% +11.68% | 12.68% +26.42% | 10.03% +39.89% | |
Revenue Growth | 20.32% -18.10% | 24.81% -7.29% | 26.76% -14.60% | 31.34% +274.14% | |
Current Ratio | 3.39 -0.11% | 3.40 +38.42% | 2.45 -9.21% | 2.70 -31.70% | |
Cash Ratio | 0.96 +109.00% | 0.46 +19.66% | 0.38 -21.56% | 0.49 -64.74% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.10 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.07 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow